🕵️ Engene Therapeutics Inc. ($ENGN)
SEC insider & ownership activity, last 12 months · CIK 1980845 · every row links its SEC filing
Insiders were quiet over the last 12 months – no open-market buys or sells. BML Investment Partners, L.P. added 7.8% → 9.9%. No red-flag 8-Ks in the window.
Insider flow
0 buyers, $0 (0 lots) · 0 sellers, $0 (0 lots)
No open-market insider transactions in the last 12 months.
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 10.0% | 13G | Nov 18, 2025 | filing ↗ | |
| Joseph Edelman | 10.0% | 13G | Nov 18, 2025 | filing ↗ | |
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | 13G | Nov 18, 2025 | filing ↗ | |
| BML Investment Partners, L.P. | 9.9% | 13G | May 14, 2026 | filing ↗ | |
| Bong Y Koh | 9.9% | 13G | Feb 14, 2025 | filing ↗ | |
| Raymond Debbane | 7.8% | 13G | May 5, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners III, L.P. | 7.1% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Co-Investment Holdings III, LLC | 7.1% | 13G | Feb 17, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners EG, L.P. | 7.1% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Management III, LLC | 7.1% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Management EG, LLC | 7.1% | 13G | Feb 17, 2026 | filing ↗ | |
| Nimish Shah | 7.1% | 13G | Feb 17, 2026 | filing ↗ | |
| Bong Y. Koh | 7.1% | 13G | Feb 17, 2026 | filing ↗ | |
| Invus Public Equities, L.P. | 6.7% | 13G | May 5, 2026 | filing ↗ | |
| Invus Public Equities Advisors, LLC | 6.7% | 13G | May 5, 2026 | filing ↗ | |
| Invus Global Management, LLC | 6.7% | 13G | May 5, 2026 | filing ↗ | |
| Siren, L.L.C. | 6.7% | 13G | May 5, 2026 | filing ↗ | |
| DEEP Track Capital, LP | 6.7% | 13G | Nov 18, 2025 | filing ↗ | |
| DEEP Track Biotechnology Master Fund, Ltd. | 6.7% | 13G | Nov 18, 2025 | filing ↗ | |
| David Kroin | 6.7% | 13G | Nov 18, 2025 | filing ↗ | |
| Anders Hove | 5.0% | 13G | Jul 22, 2026 | filing ↗ | |
| Acorn Bioventures 2, L.P. | exited | 13G | Jul 22, 2026 | filing ↗ | |
| Acorn Capital Advisors GP 2, LLC | exited | 13G | Jul 22, 2026 | filing ↗ | |
| Acorn Bioventures, L.P. | exited | 13G | Jul 22, 2026 | filing ↗ | |
| Acorn Capital Advisors GP, LLC | exited | 13G | Jul 22, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Jul 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 17, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jul 15, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jul 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 15, 2026 | filing ↗ |
| Exit or disposal costs (2.05) | Jun 16, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 16, 2026 | filing ↗ |
| Earnings (2.02) | Jun 13, 2026 | filing ↗ |
| Exit or disposal costs (2.05) | Jun 13, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 13, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 13, 2026 | filing ↗ |
| Other events (8.01) | Jun 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 13, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 9, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 5, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 5, 2026 | filing ↗ |
| Other events (8.01) | May 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 5, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Apr 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 7, 2026 | filing ↗ |
| Material agreement (1.01) | Mar 9, 2026 | filing ↗ |
| Agreement terminated (1.02) | Mar 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 9, 2026 | filing ↗ |
| Earnings (2.02) | Mar 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 9, 2026 | filing ↗ |
| Material agreement (1.01) | Jan 20, 2026 | filing ↗ |
| New financial obligation (2.03) | Jan 20, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Jan 20, 2026 | filing ↗ |